Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Bao, Shiliang Liu, Qi-chao Zhou, P. Cai, S. Anfossi, Qiaoqiao Li, Yong-hong Hu, Mengzhong Liu, J. Fu, T. Rong, Qun Li, Hui Liu (2013)
Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure patternRadiation Oncology (London, England), 8
Tsutomu Nakamura, M. Ota, K. Narumiya, Takuya Sato, T. Ohki, Masakazu Yamamoto, N. Mitsuhashi (2008)
Multimodal Treatment for Lymph Node Recurrence of Esophageal Carcinoma After Curative ResectionAnnals of Surgical Oncology, 15
Jian Zhang, F. Peng, Na Li, Yongmei Liu, Yong Xu, Lin Zhou, Jin Wang, Jiang Zhu, Meijuan Huang, Y. Gong (2012)
Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancerRadiation Oncology (London, England), 7
K. Maruyama, S. Motoyama, A. Anbai, Shuetsu Usami, Yusuke Sato, K. Shibuya, K. Yoshino, T. Nakatsu, Y. Minamiya, J. Ogawa (2011)
Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 24 3
Y. Kanda (2012)
Investigation of the freely available easy-to-use software ‘EZR' for medical statisticsBone Marrow Transplantation, 48
Hirokazu Watanabe, M. Okada, Yasushi Kaji, M. Satouchi, Yozo Sato, Y. Yamabe, H. Onaya, M. Endo, M. Sone, Y. Arai (2009)
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].Gan to kagaku ryoho. Cancer & chemotherapy, 36 13
T. Kosuga, A. Shiozaki, H. Fujiwara, D. Ichikawa, K. Okamoto, S. Komatsu, E. Otsuji (2011)
Treatment Outcome and Prognosis of Patients with Lymph Node Recurrence of Thoracic Esophageal Squamous Cell Carcinoma After Curative ResectionWorld Journal of Surgery, 35
Jin-Cheng Lu, C. Kong, H. Tao (2010)
Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma.International journal of radiation oncology, biology, physics, 78 3
Y. Shioyama, Katsumasa Nakamura, S. Ohga, S. Nomoto, Tomonari Sasaki, Toshihiro Yamaguchi, T. Toba, T. Yoshitake, H. Terashima, H. Honda (2007)
Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors.Japanese journal of clinical oncology, 37 12
H. Kato, T. Miyazaki, M. Nakajima, M. Sohda, Y. Fukai, N. Masuda, M. Fukuchi, Ryokuhei Manda, K. Tsukada, H. Kuwano (2003)
Prediction of hematogenous recurrence in patients with esophageal carcinoma.The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi, 51 11
C. Mariette, J. Balon, G. Piessen, S. Fabre, I. Seuningen, J. Triboulet (2003)
Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent diseaseCancer, 97
K. Jingu, K. Nemoto, H. Matsushita, C. Takahashi, Y. Ogawa, T. Sugawara, E. Nakata, Y. Takai, S. Yamada (2006)
Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-Fluorouracil for postoperative locoregional recurrent esophageal cancerBMC Cancer, 6
I. Kyriazanos, M. Tachibana, M. Shibakita, H. Yoshimura, S. Kinugasa, D. Dhar, T. Nakamoto, T. Fujii, N. Nagasue (2003)
Pattern of recurrence after extended esophagectomy for squamous cell carcinoma of the esophagus.Hepato-gastroenterology, 50 49
M. Shinoda, N. Ando, Ken Kato, S. Ishikura, H. Kato, Y. Tsubosa, K. Minashi, H. Okabe, Y. Kimura, T. Kawano, S. Kosugi, Y. Toh, Kenichi Nakamura, H. Fukuda (2015)
Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303)Cancer Science, 106
S. Nakagawa, T. Kanda, S. Kosugi, M. Ohashi, Tsutomu Suzuki, K. Hatakeyama (2004)
Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy.Journal of the American College of Surgeons, 198 2
Siddhartha Baxi, Bryan Burmeister, Jennifer Harvey, M. Smithers, Janine Thomas (2008)
Salvage definitive chemo‐radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: Retrospective reviewJournal of Medical Imaging and Radiation Oncology, 52
T. Matsubara, M. Ueda, T. Takahashi, T. Nakajima, M. Nishi (1996)
Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus.Journal of the American College of Surgeons, 182 4
K. Jingu, H. Ariga, K. Nemoto, K. Narazaki, R. Umezawa, K. Takeda, M. Koto, T. Sugawara, Masaki Kubozono, G. Miyata, K. Onodera, S. Yamada (2011)
Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer.International journal of radiation oncology, biology, physics, 83 1
J. Hulscher, J. Sandick, J. Tijssen, Hugo Obertop, J. Lanschot (2000)
The recurrence pattern of esophageal carcinoma after transhiatal resection.Journal of the American College of Surgeons, 191 2
Eisenhauer (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer, 45
R. Kobayashi, H. Yamashita, K. Okuma, K. Shiraishi, K. Ohtomo, K. Nakagawa (2014)
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 27 1
S. Natsugoe, M. Matsumoto, H. Okumura, Y. Uchikado, T. Setoyama, K. Sasaki, T. Sakurai, Itaru Omoto, T. Owaki, H. Shinchi, S. Ueno, S. Ishigami (2010)
Clinical course and outcome after esophagectomy with three-field lymphadenectomy in esophageal cancerLangenbeck's Archives of Surgery, 395
M. Bhansali, H. Fujita, T. Kakegawa, H. Yamana, T. Ono, S. Hikita, Y. Toh, T. Fujii, U. Tou, K. Shirouzu (1997)
Pattern of Recurrence after Extended Radical Esophagectomy with Three-Field Lymph Node Dissection for Squamous Cell Carcinoma in the Thoracic EsophagusWorld Journal of Surgery, 21
A. Font, A. Arellano, J. Fernández-Llamazares, D. Casas, J. Boix, J. Cardenal, M. Margelí, J. Manzano, A. Abad, R. Rosell (2007)
Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancerClinical and Translational Oncology, 9
K. Fakhrian, N. Gamisch, Tibor Schuster, R. Thamm, M. Molls, H. Geinitz (2012)
Salvage radiotherapy in patients with recurrent esophageal carcinomaStrahlentherapie und Onkologie, 188
Xiao Ma, K. Zhao, W. Guo, Su-Mei Yang, Xiaoli Zhu, J. Xiang, Ya-wei Zhang, hecheng li (2014)
Salvage Lymphadenectomy Versus Salvage Radiotherapy/Chemoradiotherapy for Recurrence in Cervical Lymph Node After Curative Resection of Esophageal Squamous Cell CarcinomaAnnals of Surgical Oncology, 22
K. Jingu, R. Umezawa, Takaya Yamamoto, H. Matsushita, Y. Ishikawa, M. Kozumi, Masaki Kubozono, N. Takahashi, N. Kadoya, K. Takeda (2017)
Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancerJapanese Journal of Clinical Oncology, 47
E. Tsuchida, K. Sakai, Y. Matsumoto, T. Sugita, R. Sasamoto, T. Yamanoi, H. Sueyama, Takeshi Ito, K. Sasai (2005)
Concurrent chemoradiotherapy using low-dose continuous infusion of 5-fluorouracil for postoperative regional lymph node recurrence of esophageal squamous cell carcinomaEsophagus, 2
K. Nemoto, H. Ariga, Y. Kakuto, H. Matsushita, K. Takeda, C. Takahashi, Y. Takai, S. Yamada, Y. Hosoi (2001)
Radiation therapy for loco-regionally recurrent esophageal cancer after surgery.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 61 2
K. Jingu, H. Matsushita, K. Takeda, R. Umezawa, C. Takahashi, T. Sugawara, Masaki Kubozono, Keiko Abe, T. Tanabe, Y. Shirata, Takaya Yamamoto, Y. Ishikawa, K. Nemoto (2012)
Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II studyBMC Cancer, 12
Y. Niibe, K. Hayakawa (2010)
Oligometastases and Oligo-recurrence: The New Era of Cancer TherapyJapanese Journal of Clinical Oncology, 40
Ch. Wittekind, M. Gospodarowicz, L. Sobin (2009)
TNM Classification of Malignant Tumours, 7th Edition
D. Ma, B. Tan, Mi Liu, Xianfu Li, Yeqing Zhou, You Lu (2014)
Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution studyRadiation Oncology (London, England), 9
Abstract Background The therapeutic strategies and prognostic risk factors in patients with lymph node (LN) recurrence of esophageal cancer remain controversial. We assessed clinical outcomes and prognostic factors related to the use of chemoradiotherapy (CRT) for LN recurrence of esophageal squamous cell carcinoma (ESCC) after curative resection. Methods We retrospectively evaluated survival and prognostic factors in 57 patients with LN recurrence of ESCC after curative resection. Patients received CRT using 5-fluorouracil plus cisplatin (FP) or docetaxel. Radiotherapy was delivered at 2 Gy (total dose, 60–66 Gy; median, 60 Gy). Results The median follow-up duration was 24 (range, 3–116) months. The overall survival (OS) rates at 2, 3 and 5 years were 43.7%, 36.9% and 27.6%, respectively. In the univariate analysis of OS, treatment with FP, a single LN recurrence, and a single regional recurrence were associated with a significantly better prognosis (P = 0.04, P = 0.027 and P = 0.0001, respectively). In the multivariate analysis, the combination chemotherapy regimen [hazard ratio (HR), 2.50; 95% confidence interval (CI), 1.23–5.07] and the number of the regional LNs with recurrence (HR, 5.76; 95% CI, 1.22–27.12) were independent prognostic factors. Conclusion Approximately 28% of ESCC patients with LN recurrence after curative resection could achieve long-term survival with CRT. Treatment with FP or patients with a single regional recurrence might improve the treatment outcome. postoperative lymph node recurrence of esophageal cancer, chemoradiotherapy, prognostic factor Introduction Esophagectomy remains a standard treatment for resectable esophageal cancer; however, 27.1–52.6% of patients who undergo this procedure experience postoperative recurrence, and 47.3–78.0% of these recurrences are locoregional (1–8). Treatments for such recurrences include surgical resection, chemoradiotherapy (CRT), radiotherapy (RT) or chemotherapy. A Phase II trial of CRT demonstrated this modality to be a safe and effective salvage option for postoperative locoregional recurrences of esophageal cancer (9,10). Surgery to remove recurrent lesions is also considered a good salvage option after curative resection (11–13). Long-term survivors with postoperative locoregional recurrence have been reported, and studies have suggested that patients with LN recurrence have better survival than those with local (anastomotic) recurrence (14,15). Controversy remains regarding the most effective therapeutic strategies and most accurate prognostic risk factors for LN recurrence of esophageal cancer. In our hospital, we perform CRT for LN recurrence of esophageal squamous cell carcinoma (ESCC) after curative resection. The main aim of this retrospective study was to evaluate the clinical outcomes and prognostic factors related to the use of CRT for LN recurrence after the curative resection of ESCC. Materials and methods Study population We retrospectively reviewed the medical records, RT treatment plans, and diagnostic images of patients with ESCC who satisfied the following criteria: (i) pathologically proven ESCC, (ii) Eastern Cooperative Oncology Group performance status of 0–2, (iii) treatment with definitive concurrent CRT, (iv) no other active cancer and (v) regional LN recurrence after complete resection (radical esophagectomy with 2- or 3-field LN dissection). Patients with para-aortic LN recurrence at the upper abdominal level were included. We excluded patients with distant metastases or anastomotic recurrences in addition to LN recurrence. LN recurrence was diagnosed comprehensively with ultrasonography, computed tomography, positron emission tomography and physical findings. Between April 2006 and January 2015, 57 patients with LN recurrence of ESCC after curative resection were treated with definitive concurrent CRT at Komagome Hospital and satisfied the selection criteria. Treatment External radiation therapy was administered with the 6- or 10-MV X-ray of a linear accelerator. The daily fractional dose of RT was 2.0 Gy, administered 5 days per week, and the total dose was 60–66 Gy. Four patients underwent irradiation with 66 Gy in the supraclavicular region, and the remaining 53 patients underwent irradiation with 60 Gy. A T-shaped field including the bilateral supraclavicular and mediastinal regions was used for 15 patients, and a local field covering recurrent tumors with a margin of 2–3 cm was used for 42 patients. Two-dimensional conventional RT (2D-RT) was used for 17 patients, and three-dimensional conformal RT (3D-CRT) was used for 40 patients. We used 2–4 fields to avoid the spinal cord. In the patients who received 2-field irradiation, the beam direction was changed after irradiation with 40 Gy. Before the introduction of 3D-CRT in September 2008, patients were treated with 2D-RT, in which T-shaped field was frequently used. Chemotherapy was combined with RT in all patients. Twenty-four patients received a chemotherapy regimen consisting of either 5-fluorouracil (5-FU; 700 mg/m2 on Day 1–4 per 4 weeks) plus cisplatin (cddp; 70 mg/m2 on Day 1 per 4 weeks). The remaining 33 patients received a chemotherapy regimen consisting of docetaxel (DOC; 20 mg/m2 on Day 1 per 1 week). DOC regimen was frequently used till December 2013 in patients refractory to neoadjuvant chemotherapy with FP regimen. FP regimen was used in all patients since January 2014. After the completion of therapy, the patients were followed at 1- or 3-month intervals. Follow-up evaluations included a history and physical examination, endoscopy, ultrasonography, computed tomography and positron emission tomography. The Response Evaluation Criteria in Solid Tumors criteria were used to determine the tumor response (16), and we defined disease progression as treatment failure (relapse) according to those criteria. Statistical analyses Survival was calculated from the start of treatment. Progression-free survival and overall survival (OS) were estimated with the Kaplan–Meier method, and the differences in survival in the univariate analysis were assessed with the log-rank test. Following previous studies, we entered the following parameters into the log-rank test: age (≥65 years versus <65 years), initial pathological stage [I and II versus III (UICC 2010) (17)], performance status [0 and 1 versus 2 (Eastern Cooperative Oncology Group) (18)], interval between surgery and recurrence (≥8 months versus <8 months), long diameter of the metastatic LN (≥35 mm versus <35 mm), number of recurrent nodes (single versus multiple), region of recurrent nodes (single region versus multiple regions), radiation field (T-shaped versus local), radiation technique (two-dimensional conventional RT versus three-dimensional conformal RT), and combination chemotherapy regimen (FP versus DOC) (10,12,14,15,19–25). Baseline variables with P values of <0.05 in the univariate analysis were included in the multivariable models. Cox’s regression analysis was used in the multivariate analysis. All statistical analyses were performed with EZR version 1.32 (26), and P values of <0.05 (two-sided) were considered statistically significant. Toxicity was assessed and documented according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (27). Grade 3 or worse toxicities were recorded and were defined as acute or late if they occurred within 3 months or longer than 3 months after treatment, respectively. The retrospective study protocol was reviewed and approved by the Komagome Hospital review board. Results Patients and tumor characteristics Table 1 shows a summary of patient and tumor characteristics. The median follow-up time for the patients was 24 months (range, 3–116 months). All patients completed the RT treatment, and 83.3% (20/24) and 100% (33/33) of patients received the FP or DOC regimen, respectively. The remaining patients received 1 cycle of FP. Table 1. Patient and tumor characteristics Patient and tumor characteristics No. (%) Median age no. (range) 66 (47–82) Sex no. (%) Male 46 (81) Female 11 (19) ECOG PS no.(%) 0 8 (14) 1 42 (74) 2 7 (12) Location of primary tumor no. (%) Cervix 1 (2) Upper thorax 10 (17) Middle thorax 34 (60) Lower thorax 12 (21) UICC 2010 pStage no. (%) I 8 (14) II 12 (21) III 37 (65) Interval to recurrence month (range) 7 (3–98) Lymph node recurrence site no. (%) Supraclavicular region 8 (14) Mediastinal 35 (61) Abdominal 2 (4) Multiple 12 (21) Chemotherapy regimen FP 24 (42) DOC 33 (58) Patient and tumor characteristics No. (%) Median age no. (range) 66 (47–82) Sex no. (%) Male 46 (81) Female 11 (19) ECOG PS no.(%) 0 8 (14) 1 42 (74) 2 7 (12) Location of primary tumor no. (%) Cervix 1 (2) Upper thorax 10 (17) Middle thorax 34 (60) Lower thorax 12 (21) UICC 2010 pStage no. (%) I 8 (14) II 12 (21) III 37 (65) Interval to recurrence month (range) 7 (3–98) Lymph node recurrence site no. (%) Supraclavicular region 8 (14) Mediastinal 35 (61) Abdominal 2 (4) Multiple 12 (21) Chemotherapy regimen FP 24 (42) DOC 33 (58) DOC, docetaxel; ECOG, Eastern Cooperative Oncology Group; FP, 5-fluorouracil and cisplatin; PS, performance status. Treatment outcome The overall response rate, including complete responses in 25 patients and partial responses in 22 patients, was 82.5% (Table 2). The 2-, 3- and 5-year progression-free survival rates were 26.3% (95% confidence interval [CI], 15.7–38.1), 21.7% (95% CI, 11.8–33.5) and 19.0% (95% CI, 9.6–30.9), respectively. The 2-, 3- and 5-year OS rates were 43.7% (95% CI, 30.3–56.3), 36.9% (95% CI, 23.9–49.8) and 27.6% (95% CI, 15.3–41.4), respectively, with a median survival time (MST) of 22.0 months (Fig. 1). Table 2. Treatment response Treatment response No. (%) Complete response 25 (44) Partial response 22 (38) Stable disease 10 (18) Progression of disease 0 Treatment response No. (%) Complete response 25 (44) Partial response 22 (38) Stable disease 10 (18) Progression of disease 0 Figure 1. View largeDownload slide Kaplan–Meier estimates of progression-free survival and overall survival. Figure 1. View largeDownload slide Kaplan–Meier estimates of progression-free survival and overall survival. Toxicity Grade 3 esophagitis was observed in one patient (1.8%) using T-shaped field. Grade 3 leukocytopenia was observed in six patients (25.0%) in FP regimen. No Grade 3 or worse late toxicities were observed. No Grade 4 or 5 toxicities were observed in any patient. Analysis of survival In the univariate analysis of OS, treatment with FP regimen, a single LN recurrence, and a single regional recurrence were associated with a significantly better prognosis (P = 0.04, P = 0.027, P = 0.0001, respectively; Table 3). In the multivariate analysis, the combination chemotherapy regimen [hazard ratio (HR), 2.50; 95% CI, 1.23–5.07] and the number of regional LNs with recurrence (HR, 5.76; 95% CI, 1.22–27.12) were the independent prognostic factors (Table 4). Table 3. Univariate analysis. Factor Group No. MST (months) P value Age ≥60 years 32 8 0.08 <60 years 25 22 Initial pStage I/II 20 18 0.66 III 37 22 PS 0/1 50 22 0.35 2 7 10 Interval between surgery and recurrence ≥8 months 27 24 0.35 <8 months 30 13.5 Long diameter of the metastatic lymph node ≥35 mm 6 23 0.84 <35 mm 51 21 Number of recurrent nodes Single 41 24 0.027 Multiple 16 10 Region of recurrent nodes Single 45 24 <0.001 Multiple 12 9 Radiation field T-shaped 15 21 0.38 Local 42 22 Radiation technique 2D-RT 17 19 0.64 3D-CRT 40 22 Combined chemotherapy regimen FP 24 25 0.04 DOC 33 14 Factor Group No. MST (months) P value Age ≥60 years 32 8 0.08 <60 years 25 22 Initial pStage I/II 20 18 0.66 III 37 22 PS 0/1 50 22 0.35 2 7 10 Interval between surgery and recurrence ≥8 months 27 24 0.35 <8 months 30 13.5 Long diameter of the metastatic lymph node ≥35 mm 6 23 0.84 <35 mm 51 21 Number of recurrent nodes Single 41 24 0.027 Multiple 16 10 Region of recurrent nodes Single 45 24 <0.001 Multiple 12 9 Radiation field T-shaped 15 21 0.38 Local 42 22 Radiation technique 2D-RT 17 19 0.64 3D-CRT 40 22 Combined chemotherapy regimen FP 24 25 0.04 DOC 33 14 CI, confidence interval; 3D-CRT, three-dimensional conformal radiotherapy; DOC, docetaxel; 2D-RT, two-dimensional conventional radiotherapy; FP, 5-fluorouracil and cisplatin; HR, hazard ratio; MST, median survival time; PS performance status Table 4. Multivariate analysis Factor HR 95% CI P value Combined chemotherapy regimen (DOC vs. FP) 2.5 1.23–5.07 0.011 Region of recurrent nodes (multiple vs. single) 5.76 1.22–27.12 0.027 Factor HR 95% CI P value Combined chemotherapy regimen (DOC vs. FP) 2.5 1.23–5.07 0.011 Region of recurrent nodes (multiple vs. single) 5.76 1.22–27.12 0.027 CI, confidence interval; DOC, docetaxel; FP, 5-fluorouracil and cisplatin; HR, hazard ratio. Discussion We retrospectively evaluated treatment outcomes and prognostic factors in a group of patients treated with CRT for LN recurrence of ESCC after curative resection. Our results showed that ~28% of patients could achieve long-term survival with CRT. The results also suggested that treatment with FP regimen or patients with a single regional recurrence might improve the treatment outcome. Other studies have examined the efficacy of CRT for treating the locoregional recurrence of esophageal cancer after curative resection (Table 5) (9,10,21,24,25,28–30) and have reported generally high response rates of >70%. However, survival varied greatly, with the MST ranging from 13 to 43 months, the 2-year OS ranging from 31% to 57%, and the 3-year OS ranging from 10.5% to 51.8%. Several factors might account for this discrepancy. First, those studies were primarily retrospective studies with small sample sizes, and therefore, selection bias may exist. Second, some studies included patients with anastomotic recurrence. Third, even among patients receiving CRT, the chemotherapy regimens were diverse. Finally, the treatment target volume definition and irradiation dose also varied. These factors could have had a remarkable influence on the clinical outcomes. Our study also had this discrepancy. However, the clinical outcome in our study was generally favorable compared with the outcomes of these previous studies. Table 5. Content and results of previous studies of outcomes for chemoradiotherapy for the treatment of postoperative recurrent esophageal cancer First author Year No. Chemotherapy regimen Median prescribed dose (Gy) Response rate (%) 2-/3-year OS rate (%) MST (months) Tsuchida 2005 14 FP 60 86 57/NA 27 Nakamura 2008 22 FP or NDP + 5FU 56 82 NA/26.6 20.3 Lu 2010 31 FP 60 97 NA/10.5 17 Maruyama 2010 23 FP 60 60 31/24 13 Jingu 2012 30 NDP + 5FU 60 72 NA/38.4 21 Zhang 2012 50 FP or PTX + CDDP 60 72 NA/14 13.3 Bao 2013 83 FP or DOC + CDDP 60 75.9 NA/51.8 43 Ma 2014 49 CDDP NA (62–70) 91.8 NA/46.9 35 Kobayashi 2014 42 FP or NDP + S1 60 97.6 51.3/41.1 24.3 Present study 2017 57 FP or DOC 60 82.5 43.9/35.5 22 First author Year No. Chemotherapy regimen Median prescribed dose (Gy) Response rate (%) 2-/3-year OS rate (%) MST (months) Tsuchida 2005 14 FP 60 86 57/NA 27 Nakamura 2008 22 FP or NDP + 5FU 56 82 NA/26.6 20.3 Lu 2010 31 FP 60 97 NA/10.5 17 Maruyama 2010 23 FP 60 60 31/24 13 Jingu 2012 30 NDP + 5FU 60 72 NA/38.4 21 Zhang 2012 50 FP or PTX + CDDP 60 72 NA/14 13.3 Bao 2013 83 FP or DOC + CDDP 60 75.9 NA/51.8 43 Ma 2014 49 CDDP NA (62–70) 91.8 NA/46.9 35 Kobayashi 2014 42 FP or NDP + S1 60 97.6 51.3/41.1 24.3 Present study 2017 57 FP or DOC 60 82.5 43.9/35.5 22 CDDP, cisplatin; DOC, docetaxel; 5FU, 5-fluorouracil; FP, 5-fluorouracil plus cisplatin; MST, median survival time; NA, information not available; NDP, nedaplatin; OS, overall survival; PTX, paclitaxel. Several prognostic factors for ESCC have been suggested (Table 6). For example, high RT dose, single node recurrence, single regional recurrence and the use of a combination taxane-based plus CDDP regimen are reportedly associated with better outcomes (10,12,14,15,19–25). Among studies reporting prognostic factors, we focused on those of Bao et al. and Zhang et al. In the former, a total of 83 patients with postoperative locoregional recurrence of ESCC were treated with concurrent CRT. Patients treated with the DOC + CDDP regimen had a 3-year OS rate (59.2%) superior to that of patients receiving FP regimen (43.3%) (24). In the latter study, 50 patients with postoperative locoregional recurrence of ESCC were treated with concurrent CRT. Patients who received the paclitaxel + CDDP regimen had an MST (median, 16.3 months) superior to that of patients who received FP regimen (median, 9.8 months) (25). These previous studies reported excellent results for patients receiving RT combined with a taxane-based regimen in a comparison with a regimen of RT combined with FP (FP-RT). However, the outcomes of treatment with RT combined with DOC alone (DOC-RT; MST, 14 months; 3-year OS rate, 30.5%) were worse than those of treatment with FP-RT (MST, 25 months; 3-year OS rate, 43.9%) in our study. These results suggest that CDDP may be a key drug in the RT treatment of postoperative LN recurrence of ESCC. Table 6. Prognostic factors confirmed in previous studies First author Factor Good Poor Shioyama Long diameter of the metastatic lymph node <35 mm ≥35 mm Nakamura Number of recurrent nodes Single Multiple Kosuga, Jingu, Ma Region of recurrent nodes Single Multiple Nemoto Interval between surgery and recurrence ≥8 months <8 months Zhang Dose ≥60 Gy <60 Gy Fakhrian RT technique 3D-CRT 2D-RT Bao Combined chemotherapy regimen DOC + CDDP FP Zhang PTX + CDDP FP Present study Region of recurrent nodes Single Multiple Combined chemotherapy regimen FP DOC First author Factor Good Poor Shioyama Long diameter of the metastatic lymph node <35 mm ≥35 mm Nakamura Number of recurrent nodes Single Multiple Kosuga, Jingu, Ma Region of recurrent nodes Single Multiple Nemoto Interval between surgery and recurrence ≥8 months <8 months Zhang Dose ≥60 Gy <60 Gy Fakhrian RT technique 3D-CRT 2D-RT Bao Combined chemotherapy regimen DOC + CDDP FP Zhang PTX + CDDP FP Present study Region of recurrent nodes Single Multiple Combined chemotherapy regimen FP DOC CDDP, cisplatin; 3D-CRT, three-dimensional conformal; DOC, docetaxel; 2D-RT, two-dimensional conventional radiotherapy; FP, 5-fluorouracil plus cisplatin; PS, performance status; PTX, paclitaxel. No previous studies have examined the effectiveness of RT combined with DOC alone (DOC-RT) for the treatment of postoperative LN recurrences of ESCC. The results of a Phase I trial demonstrated promising efficacy and an acceptable toxicity profile for DOC-RT in patients with inoperable esophageal cancer (31). Hematological toxicity (<10% Grade 3/4 toxicities) with this treatment was lower than that with FP-RT (26% Grade 3/4 toxicities). However, the MST (6 months) and 1-year OS (35%) were lower than those with FP-RT (MST, 13.1 months; 1-year OS, 56%) (32). The results of our study demonstrated that DOC-RT is a safe treatment for postoperative LN recurrences of ESCC, and the MST and OS for patients with DOC-RT were also lower than for those with FP-RT. Previous studies have reported excellent results with CRT for esophageal cancer patients with recurrence in a single region or single node after curative resection (8,10,12,14,22). Outcomes in patients with recurrence in a single region or single node were also significantly better than those for patients with recurrence in multiple regions or multiple nodes in our univariate analysis. This result supports our hypothesis that the concept of oligo-recurrence might be applicable to postoperative esophageal cancer (33). With regard to RT field size, a previous study has reported the use of CRT for postoperative locoregional recurrence. Jingu et al. have reported that the overall survival and irradiated-field control rates are significantly better in patients treated with involved field irradiation than in those treated with elective nodal irradiation (34). However, our study showed that RT field size was not associated with prognosis. With regard to toxicities, we considered that T-shaped field including elective irradiation was not necessary. The present study has several limitations associated with its retrospective design. First, we could not demonstrate a survival benefit of treatment with CRT compared with chemotherapy alone. A previous study suggested that CRT (MST, 20.3 months) is superior to chemotherapy alone or palliative care (MST, <12 months) for LN recurrence after esophagectomy (12). In our study, the MST was 24 months for patients with recurrence in a single region or single node. Given this result, CRT may be a recommended minimum treatment for patients with oligo-recurrence in the LNs in esophageal cancer. Second, this study has selection biases. We enrolled patients with LN recurrence, and there was non-uniformity in the combined chemotherapy regimens and RT techniques. Therefore, a prospective study with a uniform strategy such as FP-RT for cervical LN recurrence is essential. In conclusion, we found that CRT was a safe and effective salvage treatment for LN recurrence after curative resection in ESCC. Approximately 28% of patients could achieve long-term survival with CRT. Our results also suggest that treatment with FP regimen or patients with a single regional recurrence may provide superior outcomes. Conflict of interest statement The authors declare that they have no competing interests. Authors' contributions T.K. prepared the manuscript and the literature search; T.K. reviewed and edited the manuscript; and T.K., K.N., K.S. and K.K. reviewed the manuscript. All authors read and approved the final manuscript. Ethical statement This study used no human or animal subjects. Abbreviations ESCC esophageal squamous cell carcinoma; RT radiotherapy CRT chemoradiotherapy LN lymph node 2D-RT two-dimensional conventional radiotherapy 3D-CRT three-dimensional conformal radiotherapy OS overall survival MST median survival time FP 5-fluorouracil and cisplatin DOC docetaxel References 1 Bhansali MS, Fujita H, Kakegawa T, et al. . Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg 1997; 21: 275– 81. Google Scholar CrossRef Search ADS PubMed 2 Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg 2000; 191: 143– 8. Google Scholar CrossRef Search ADS PubMed 3 Kato H, Miyazaki T, Nakajima M, et al. . Prediction of hematogenous recurrence in patients with esophageal carcinoma. Jpn J Thorac Cardiovasc Surg 2003; 51: 599– 608. Google Scholar CrossRef Search ADS PubMed 4 Kyriazanos ID, Tachibana M, Shibakita M, et al. . Pattern of recurrence after extended esophagectomy for squamous cell carcinoma of the esophagus. Hepatogastroenterology 2003; 50: 115– 20. Google Scholar PubMed 5 Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616– 23. Google Scholar CrossRef Search ADS PubMed 6 Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004; 198: 205– 11. Google Scholar CrossRef Search ADS PubMed 7 Natsugoe S, Matsumoto M, Okumura H, et al. . Clinical course and outcome after esophagectomy with three-field lymphadenectomy in esophageal cancer. Langenbecks Arch Surg 2010; 395: 341– 6. Google Scholar CrossRef Search ADS PubMed 8 Jingu K, Ariga H, Nemoto K, et al. . Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 83: 172– 7. Google Scholar CrossRef Search ADS PubMed 9 Jingu K, Nemoto K, Matsushita H, et al. . Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer 2006; 6: 50. Google Scholar CrossRef Search ADS PubMed 10 Ma DY, Tan BX, Liu M, Li XF, Zhou YQ, Lu Y. Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study. Radiat Oncol 2014; 9: 28. Google Scholar CrossRef Search ADS PubMed 11 Matsubara T, Ueda M, Takahashi T, Nakajima T, Nishi M. Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J Am Coll Surg 1996; 182: 340– 6. Google Scholar PubMed 12 Nakamura T, Ota M, Narumiya K, et al. . Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol 2008; 15: 2451– 7. Google Scholar CrossRef Search ADS PubMed 13 Ma X, Zhao K, Guo W, et al. . Salvage lymphadenectomy versus salvage radiotherapy/chemoradiotherapy for recurrence in cervical lymph node after curative resection of esophageal squamous cell carcinoma. Ann Surg Oncol 2015; 22: 624– 9. Google Scholar CrossRef Search ADS PubMed 14 Jingu K, Matsushita H, Takeda K, et al. . Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. BMC Cancer 2012; 12: 542. Google Scholar CrossRef Search ADS PubMed 15 Baxi SH, Burmeister B, Harvey JA, Smithers M, Thomas J. Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review. J Med Imaging Radiat Oncol 2008; 52: 583– 7. Google Scholar CrossRef Search ADS PubMed 16 Eisenhauer EA, Therasse P, Bogaerts J, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228– 47. Google Scholar CrossRef Search ADS PubMed 17 Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer. TNM Classification of Malignant Tumours . 7th edn. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell, 2010. 18 Common Toxicity Criteria, Version2.0 Publish Date April 30. 1999. 19 Nemoto K, Ariga H, Kakuto Y, et al. . Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol 2001; 61: 165– 8. Google Scholar CrossRef Search ADS PubMed 20 Shioyama Y, Nakamura K, Ohga S, et al. . Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol 2007; 37: 918– 23. Google Scholar CrossRef Search ADS PubMed 21 Lu J, Kong C, Tao H. Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010; 78: 710– 4. Google Scholar CrossRef Search ADS PubMed 22 Kosuga T, Shiozaki A, Fujiwara H, et al. . Treatment outcome and prognosis of patients with lymph node recurrence of thoracic esophageal squamous cell carcinoma after curative resection. World J Surg 2011; 35: 798– 804. Google Scholar CrossRef Search ADS PubMed 23 Fakhrian K, Gamisch N, Schuster T, Thamm R, Molls M, Geinitz H. Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol 2012; 188: 136– 42. Google Scholar CrossRef Search ADS PubMed 24 Bao Y, Liu S, Zhou Q, et al. . Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern. Radiat Oncol 2013; 8: 241. Google Scholar CrossRef Search ADS PubMed 25 Zhang J, Peng F, Li N, et al. . Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer. Radiat Oncol 2012; 7: 93. Google Scholar CrossRef Search ADS PubMed 26 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452– 8. Google Scholar CrossRef Search ADS PubMed 27 National Cancer Institute (U.S.). Common Terminology Criteria for Adverse Events (CTCAE) . Rev. edn. Bethesda, MD.: U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute, 2009. 28 Tsuchida E, Sakai K, Yasuo M, et al. . Concurrent chemoradiotherapy using low-dose continuous infusion of 5-fluorouracil for postoperative regional lymph node recurrence of esophageal squamous cell carcinoma. Esophagus 2005; 2: 25– 31. Google Scholar CrossRef Search ADS 29 Maruyama K, Motoyama S, Anbai A, et al. . Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy. Dis Esophagus 2011; 24: 166– 71. Google Scholar CrossRef Search ADS PubMed 30 Kobayashi R, Yamashita H, Okuma K, Shiraishi K, Ohtomo K, Nakagawa K. Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer. Dis Esophagus 2014; 27: 72– 8. Google Scholar CrossRef Search ADS PubMed 31 Font A, Arellano A, Fernandez-Llamazares J, et al. . Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clin Transl Oncol 2007; 9: 177– 82. Google Scholar CrossRef Search ADS PubMed 32 Shinoda M, Ando N, Kato K, et al. . Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 2015; 106: 407– 12. Google Scholar CrossRef Search ADS PubMed 33 Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010; 40: 107– 11. Google Scholar CrossRef Search ADS PubMed 34 Jingu K, Umezawa R, Yamamoto T, et al. . Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer. Jpn J Clin Oncol 2017; 47: 200– 5. Google Scholar PubMed © The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
Japanese Journal of Clinical Oncology – Oxford University Press
Published: Mar 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.